Literature DB >> 20235333

Themes of liver transplantation.

Thomas E Starzl1, John J Fung.   

Abstract

Liver transplantation was the product of five interlocking themes. These began in 1958-1959 with canine studies of then theoretical hepatotrophic molecules in portal venous blood (Theme I) and with the contemporaneous parallel development of liver and multivisceral transplant models (Theme II). Further Theme I investigations showed that insulin was the principal, although not the only, portal hepatotrophic factor. In addition to resolving long-standing controversies about the pathophysiology of portacaval shunt, the hepatotrophic studies blazed new trails in the regulation of liver size, function, and regeneration. They also targeted inborn metabolic errors (e.g., familial hyperlipoproteinemia) whose palliation by portal diversion presaged definitive correction with liver replacement. Clinical use of the Theme II transplant models depended on multiple drug immunosuppression (Theme III, Immunology), guided by an empirical algorithm of pattern recognition and therapeutic response. Successful liver replacement was first accomplished in 1967 with azathioprine, prednisone, and antilymphoid globulin. With this regimen, the world's longest surviving liver recipient is now 40 years postoperative. Incremental improvements in survival outcome occurred (Theme IV) when azathioprine was replaced by cyclosporine (1979), which was replaced in turn by tacrolimus (1989). However, the biologic meaning of alloengraftment remained enigmatic until multilineage donor leukocyte microchimerism was discovered in 1992 in long-surviving organ recipients. Seminal mechanisms were then identified (clonal exhaustion-deletion and immune ignorance) that linked organ engraftment and the acquired tolerance of bone marrow transplantation and eventually clarified the relationship of transplantation immunology to the immunology of infections, neoplasms, and autoimmune disorders. With this insight, better strategies of immunosuppression have evolved. As liver and other kinds of organ transplantation became accepted as healthcare standards, the ethical, legal, equity, and the other humanism issues of Theme V have been resolved less conclusively than the medical-scientific problems of Themes I-IV.

Entities:  

Mesh:

Year:  2010        PMID: 20235333      PMCID: PMC4507423          DOI: 10.1002/hep.23595

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  65 in total

Review 1.  Transplantation tolerance from a historical perspective.

Authors:  T E Starzl; R M Zinkernagel
Journal:  Nat Rev Immunol       Date:  2001-12       Impact factor: 53.106

2.  Homotransplantation of multiple visceral organs.

Authors:  T E STARZL; H A KAUPP; D R BROCK; G W BUTZ; J W LINMAN
Journal:  Am J Surg       Date:  1962-02       Impact factor: 2.565

3.  Transplantation of multiple abdominal viscera.

Authors:  T E Starzl; M I Rowe; S Todo; R Jaffe; A Tzakis; A L Hoffman; C Esquivel; K A Porter; R Venkataramanan; L Makowka
Journal:  JAMA       Date:  1989-03-10       Impact factor: 56.272

4.  Equitable allocation of extrarenal organs: with special reference to the liver.

Authors:  T E Starzl; R D Gordon; A Tzakis; S Staschak; V Fioravanti; B Broznick; L Makowka; H T Bahnson
Journal:  Transplant Proc       Date:  1988-02       Impact factor: 1.066

5.  Long-term survival after renal transplantation in humans: (with special reference to histocompatibility matching, thymectomy, homograft glomerulonephritis, heterologous ALG , AND RECIPIENT MALIGNANCY).

Authors:  T E Starzl; K A Porter; G Andres; C G Halgrimson; R Hurwitz; G Giles; P I Terasaki; I Penn; G T Schroter; J Lilly; S J Starkie; C W Putnam
Journal:  Ann Surg       Date:  1970-09       Impact factor: 12.969

6.  Orthotopic homotransplantation of the human liver.

Authors:  T E Starzl; C G Groth; L Brettschneider; I Penn; V A Fulginiti; J B Moon; H Blanchard; A J Martin; K A Porter
Journal:  Ann Surg       Date:  1968-09       Impact factor: 12.969

7.  National Institutes of Health Consensus Development Conference on Liver Transplantation. Sponsored by the National Institute of Arthritis, Diabetes, and Digestive and Kidney Diseases and the National Institutes of Health Office of Medical Applications of Research.

Authors: 
Journal:  Hepatology       Date:  1984 Jan-Feb       Impact factor: 17.425

8.  Abdominal organ cluster transplantation for the treatment of upper abdominal malignancies.

Authors:  T E Starzl; S Todo; A Tzakis; L Podesta; L Mieles; A Demetris; L Teperman; R Selby; W Stevenson; A Stieber
Journal:  Ann Surg       Date:  1989-09       Impact factor: 12.969

9.  Effects of insulin, glucagon, and insuling/glucagon infusions on liver morphology and cell division after complete portacaval shunt in dogs.

Authors:  T E Starzl; K Watanabe; K A Porter; C W Putnam
Journal:  Lancet       Date:  1976-04-17       Impact factor: 79.321

10.  Intestinal transplantation in composite visceral grafts or alone.

Authors:  S Todo; A G Tzakis; K Abu-Elmagd; J Reyes; K Nakamura; A Casavilla; R Selby; B M Nour; H Wright; J J Fung
Journal:  Ann Surg       Date:  1992-09       Impact factor: 12.969

View more
  28 in total

1.  Anthony Cerami Award in Translational Medicine: A Journey in Science: The Birth of Organ Transplantation with Particular Reference to Alloengraftment Mechanisms.

Authors:  Thomas E Starzl
Journal:  Mol Med       Date:  2015-06-25       Impact factor: 6.354

2.  Technical Aspects of Orthotopic Liver Transplantation-a Survey-Based Study Within the Eurotransplant, Swisstransplant, Scandiatransplant, and British Transplantation Society Networks.

Authors:  Zoltan Czigany; Marcus N Scherer; Johann Pratschke; Markus Guba; Silvio Nadalin; Arianeb Mehrabi; Gabriela Berlakovich; Xavier Rogiers; Jacques Pirenne; Jan Lerut; Zoltan Mathe; Philipp Dutkowski; Bo-Göran Ericzon; Massimo Malagó; Nigel Heaton; Wenzel Schöning; Jan Bednarsch; Ulf Peter Neumann; Georg Lurje
Journal:  J Gastrointest Surg       Date:  2018-08-10       Impact factor: 3.452

Review 3.  Liver transplantation in treatment of colorectal liver metastases.

Authors:  Morten Hagness
Journal:  Hepat Oncol       Date:  2015-04-27

Review 4.  Potential approaches to improve the outcomes of donation after cardiac death liver grafts.

Authors:  Paria Mahboub; Adel Bozorgzadeh; Paulo N Martins
Journal:  World J Transplant       Date:  2016-06-24

5.  Interleukin-17 plays a critical role in the acute rejection of intestinal transplantation.

Authors:  Jian-Jun Yang; Fan Feng; Liu Hong; Li Sun; Meng-Bin Li; Ran Zhuang; Feng Pan; Ying-Mei Wang; Wei-Zhong Wang; Guo-Sheng Wu; Hong-Wei Zhang
Journal:  World J Gastroenterol       Date:  2013-02-07       Impact factor: 5.742

6.  Overexpression of transcription factor Foxa2 and Hnf1α induced rat bone mesenchymal stem cells into hepatocytes.

Authors:  Yi Ding; Cuifang Chang; Zhipeng Niu; Keqiang Dai; Xiaofang Geng; Deming Li; Jianlin Guo; Cunshuan Xu
Journal:  Cytotechnology       Date:  2016-01-21       Impact factor: 2.058

7.  Evaluation of a novel hybrid bioartificial liver based on a multi-layer flat-plate bioreactor.

Authors:  Xiao-Lei Shi; Yue Zhang; Xue-Hui Chu; Bing Han; Jin-Yang Gu; Jiang-Qiang Xiao; Jia-Jun Tan; Zhong-Ze Gu; Hao-Zhen Ren; Xian-Wen Yuan; Yi-Tao Ding
Journal:  World J Gastroenterol       Date:  2012-07-28       Impact factor: 5.742

Review 8.  Review of the early diagnoses and assessment of rejection in vascularized composite allotransplantation.

Authors:  Ravi Starzl; Gerald Brandacher; W P Andrew Lee; Jaime Carbonell; Wensheng Zhang; Jonas Schnider; Vijay Gorantla; Stefan Schneeberger; Xin Xiao Zheng
Journal:  Clin Dev Immunol       Date:  2013-02-13

Review 9.  Pluripotent stem cell-derived hepatocyte-like cells.

Authors:  R E Schwartz; H E Fleming; S R Khetani; S N Bhatia
Journal:  Biotechnol Adv       Date:  2014-01-16       Impact factor: 14.227

10.  Predicting Liver Transplant Capacity Using Discrete Event Simulation.

Authors:  Hector Toro-Díaz; Maria E Mayorga; A Sidney Barritt; Eric S Orman; Stephanie B Wheeler
Journal:  Med Decis Making       Date:  2014-11-12       Impact factor: 2.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.